Immunocore has been granted a patent for T cell receptors (TCRs) that target the HLA-A*02 restricted peptide SLLQHLIGL from the PRAME cancer antigen. The invention includes a heterodimeric TCR-anti-CD3 antibody fusion molecule, designed for potential use in cancer immunotherapy. GlobalData’s report on Immunocore gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Immunocore, Peptide pharmacophores was a key innovation area identified from patents. Immunocore's grant share as of June 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
T cell receptors for cancer immunotherapy targeting prame
The granted patent US12018062B2 describes a novel heterodimeric T-cell receptor (TCR)-anti-CD3 antibody fusion molecule designed for therapeutic applications, particularly in cancer treatment. The fusion molecule consists of two polypeptide chains: one containing a TCR alpha chain variable domain and the other containing a TCR beta chain variable domain. Specific amino acid sequences for these domains are provided, including SEQ ID NO: 6, 7, 9, 11, 17, and 18. The claims also detail various configurations of the TCR, including single-chain formats and modifications to the constant domain sequences to enhance functionality. The anti-CD3 component can take several forms, such as Fab fragments or single-chain variable fragments (scFv), with specific sequences outlined for the scFv variants.
Additionally, the patent outlines a pharmaceutical composition that includes the heterodimeric TCR-anti-CD3 antibody fusion molecule, combined with acceptable carriers or excipients. A method for treating cancer is also described, which involves administering a therapeutically effective dose of this composition to patients. The treatment is particularly aimed at cancers expressing the PRAME antigen, including melanoma, lung cancer, breast cancer, and several others. The administration method specified is injection, indicating a direct delivery approach for therapeutic efficacy. This patent represents a significant advancement in targeted cancer therapies, leveraging the specificity of TCRs and the immune-modulating properties of anti-CD3 antibodies.
To know more about GlobalData’s detailed insights on Immunocore, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
